SARS CoV-2 Seroprevalence Among HIV-Negative Participants Using Tenofovir/Emtricitabine Based PrEP in 2020 – A Sub-study of ANRS PREVENIR and INSERM SAPRIS-Sero Cohorts

Constance Delaugerre,Lambert Assoumou,Sarah Maylin,Marine Minier,Audrey Gabassi,Michèle Genin,Lydie Beniguel,Jade Ghosn,Xavier de Lamballerie,Mayssam El Mouhebb,Dominique Costagliola,Fabrice Carrat,Jean-Michel Molina

Open Forum Infectious Diseases（2022）

引用 5|浏览3

暂无评分

摘要

Abstract The potential preventive efficacy of tenofovir/emtricitabine on SARS-CoV-2 infection was assessed in HIV pre-exposition prophylaxis (PrEP) users. Prevalence of SARS-CoV-2 IgG between May and October 2020 was similar in PrEP users and in a matched population-based cohort suggesting that tenofovir/emtricitabine has no role in reducing the risk of SARS-CoV-2 acquisition.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要